- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: ACA Deadline Extended for Consumers With Discontinued Plans
What we're reading, October 25, 2016: individuals with discontinued Obamacare plans will have a special enrollment period; Arizona governor orders limits on opioid prescriptions; and the FDA aims to speed up generic drug reviews.
Individuals who are currently enrolled in an Affordable Care Act plan that will be discontinued next year when the insurer leaves the market will have extra time to get coverage. People who lost their coverage can sign up as late as December 31 and still have coverage begin on January 1 if they can attest to the situation, reported The Wall Street Journal. However, if they miss that deadline, their special enrollment period doesn’t end until March 1—they will simply have a lapse in coverage. The Obama administration expects 13.8 million individuals to select plans for 2017.
In Arizona, the governor has ordered limits on opioid prescriptions in the state’s employee insurance plan and Medicaid plan. The Washington Times reported that the order would limit the initial prescription to just 7 days. In addition, a pre-approval will no longer be needed for people with state-provided insurance to be prescribed a drug used to treat recovering addicts.
The FDA is aiming to speed up the review process for generic drugs. According to Roll Call, the agency is committing to a 10-month review, but there would be an 8-month timeline for applications that could impact access or cost. For instance, drugs that could impact public health, address a drug shortage, or introduce generic competition to the market would be eligible for the accelerated timeline.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
